3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Genitourinary
2
Dermatologic
2
Tumor-Agnostic
1
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
CNS
1
Conditions
Lymphoma
1
Leukemia
1
Interventions
venetoclax
190
Cyclophosphamide
123
Azacitidine
112
Cytarabine
108
fludarabine
91
Specimen Handling
74
Biopsy
53
Daunorubicin
42
Methotrexate
41
Dexamethasone
38
Rituximab
34
blinatumomab
32
Vincristine
32
Decitabine
31
fludarabine phosphate
30
Injections
28
Granulocyte Colony-Stimulating Factor
28
Whole-Body Irradiation
26
Magnetic Resonance Spectroscopy
26
obinutuzumab
25
Idarubicin
25
acalabrutinib
23
Prednisone
23
Mycophenolic Acid
23
Melphalan
21
Busulfan
21
gilteritinib
19
Mercaptopurine
19
Doxorubicin
19
ibrutinib
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
capivasertib
×
Other hematologic neoplasm
×
Clear all
NCT07294677
2026-03-04
CAVALRY
University of Chicago
Phase 1/2
Recruiting
104 enrolled